Compare EXPI & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXPI | GERN |
|---|---|---|
| Founded | 2008 | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2010 | N/A |
| Metric | EXPI | GERN |
|---|---|---|
| Price | $6.76 | $1.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $9.75 | $2.17 |
| AVG Volume (30 Days) | 832.1K | ★ 15.7M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,147,681.00 | N/A |
| Revenue This Year | $6.26 | $26.91 |
| Revenue Next Year | $5.50 | $43.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 220.39 | N/A |
| 52 Week Low | $5.66 | $1.04 |
| 52 Week High | $12.23 | $2.01 |
| Indicator | EXPI | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 60.03 | 32.86 |
| Support Level | $5.68 | $1.24 |
| Resistance Level | $6.87 | $1.49 |
| Average True Range (ATR) | 0.23 | 0.09 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 81.56 | 0.00 |
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.